Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
Aktis Oncology cash
Cash and short-term investments held at the end of each period.
Aktis Oncology's cash was $492.90M at Sep 30, 2026. For fiscal 2025 it was $37.78M, down 1.4% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.78M | -1.4% |
| FY2024 | Dec 31, 2024 | $38.31M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $492.90M | +173.4% |
| Q2 FY2026 | Jun 30, 2026 | $517.30M | +369.4% |
| Q1 FY2026 | Mar 31, 2026 | $538.50M | +824.5% |
| Q4 FY2025 | Dec 31, 2025 | $37.78M | -1.4% |
| Q3 FY2025 | Sep 30, 2025 | $180.25M | – |
| Q2 FY2025 | Jun 30, 2025 | $110.22M | – |
| Q1 FY2025 | Mar 31, 2025 | $58.25M | – |
| Q4 FY2024 | Dec 31, 2024 | $38.31M | – |
See a number that looks wrong?